Afanat– Afatinib 30 mg Tablet

AFANAT 30 mg Tablet contains afatinib, a targeted anticancer medicine used in specialized treatment plans for certain types of non-small cell lung cancer. It belongs to the tyrosine kinase inhibitor class and works by blocking specific signaling pathways that can promote the growth and spread of cancer cells. This targeted approach supports personalized cancer treatment, particularly when specific molecular changes are present. The tablet formulation provides a convenient oral treatment option and can be incorporated into carefully planned oncology regimens. Treatment is prescribed and monitored by qualified healthcare professionals based on the individual’s diagnosis and therapeutic needs.